GSK To End Doctor Drug Promotion In Wake Of China Scandal
This article was originally published in PharmAsia News
Executive Summary
In the wake of China's charges against GlaxoSmithKline local officials for compensating physicians for promoting its products, the British drug maker has announced it would halt the activity worldwide.